MDxHealth (NASDAQ:MDXH) Rating Lowered to “Market Perform” at William Blair

MDxHealth (NASDAQ:MDXH) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued on Thursday, MarketBeat.com reports.

Several other research firms have also weighed in on MDXH. BTIG Research cut their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

MDxHealth Price Performance

Shares of MDxHealth stock traded down $1.00 during trading on Thursday, hitting $0.95. 3,705,051 shares of the company were exchanged, compared to its average volume of 196,008. The firm has a market capitalization of $47.03 million, a P/E ratio of -1.45 and a beta of 1.60. The firm’s fifty day moving average price is $2.52 and its 200 day moving average price is $3.27. MDxHealth has a 1-year low of $0.96 and a 1-year high of $5.33.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The firm had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million. As a group, equities research analysts anticipate that MDxHealth will post -0.41 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Intesa Sanpaolo Wealth Management acquired a new stake in shares of MDxHealth during the fourth quarter worth $36,000. Lido Advisors LLC bought a new position in MDxHealth during the 3rd quarter worth about $48,000. GSA Capital Partners LLP acquired a new stake in shares of MDxHealth in the 3rd quarter valued at about $48,000. Squarepoint Ops LLC bought a new stake in shares of MDxHealth in the fourth quarter valued at about $51,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth during the third quarter worth about $53,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.